Literature DB >> 8647625

Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells.

L Borsi1, G Allemanni, B Gaggero, L Zardi.   

Abstract

In cultured normal human fibroblasts, 2 main tenascin-C (TN-C) isoforms are generated by alternative splicing of the single TN-C primary transcript, 8 type III repeats being included or omitted in the mRNA. In these cultured cells, small pH variations of the culture medium (from 7.2 to 6.8) strikingly modify the alternative splicing pattern of the TN-C primary transcript. We report that malignantly transformed cells do not respond to extracellular pH variations as normal cells do. Indeed, malignantly transformed cells kept in culture media at pH values from 6.6 to 7.6 show no variations in the splicing pattern of the TN-C primary transcript and accumulate almost exclusively the large TN-C mRNA. These observations may explain the preferential accumulation in vivo of the large TN-C isoform in the extracellular matrix of different types of neoplasia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647625     DOI: 10.1002/(SICI)1097-0215(19960529)66:5<632::AID-IJC9>3.0.CO;2-U

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

Review 1.  Tenascins and the importance of adhesion modulation.

Authors:  Ruth Chiquet-Ehrismann; Richard P Tucker
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-05-01       Impact factor: 10.005

2.  Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?

Authors:  Carlo Genova; Erika Rijavec; Francesco Grossi
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 3.  Interfering with pH regulation in tumours as a therapeutic strategy.

Authors:  Dario Neri; Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

4.  Ultrastructural morphology and expression of proteoglycans, betaig-h3, tenascin-C, fibrillin-1, and fibronectin in bullous keratopathy.

Authors:  S Akhtar; A J Bron; N R Hawksworth; R E Bonshek; K M Meek
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

5.  Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.

Authors:  B Carnemolla; P Castellani; M Ponassi; L Borsi; S Urbini; G Nicolo; A Dorcaratto; G Viale; G Winter; D Neri; L Zardi
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 6.  Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer.

Authors:  Alexander Berndt; Petra Richter; Hartwig Kosmehl; Marcus Franz
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 7.  Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.

Authors:  Patrizia Murer; Dario Neri
Journal:  N Biotechnol       Date:  2019-04-13       Impact factor: 5.079

Review 8.  Revisiting the Tenascins: Exploitable as Cancer Targets?

Authors:  Richard P Tucker; Martin Degen
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

9.  MSC response to pH levels found in degenerating intervertebral discs.

Authors:  Karin Wuertz; Karolyn Godburn; James C Iatridis
Journal:  Biochem Biophys Res Commun       Date:  2009-01-06       Impact factor: 3.575

10.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.